Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

por Satzger, I, Schaefer, T, Kuettler, U, Broecker, V, Voelker, B, Ostertag, H, Kapp, A, Gutzmer, R
Publicado 2008

Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model

por Gschwandtner, M, Mildner, M, Mlitz, V, Gruber, F, Eckhart, L, Werfel, T, Gutzmer, R, Elias, P M, Tschachler, E
Publicado 2013

Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?

por Ivanyi, P., Park-Simon, T., Christiansen, H., Gutzmer, R., Vogel, A., Heuser, M., Golpon, H., Hillemanns, P., Haier, J.
Publicado 2021

Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells

por Pincha, M, Salguero, G, Wedekind, D, Sundarasetty, B S, Lin, A, Kasahara, N, Brugman, M H, Jirmo, A C, Modlich, U, Gutzmer, R, Büsche, G, Ganser, A, Stripecke, R
Publicado 2011

Lentivirus-induced ‘Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma

por Sundarasetty, B S, Chan, L, Darling, D, Giunti, G, Farzaneh, F, Schenck, F, Naundorf, S, Kuehlcke, K, Ruggiero, E, Schmidt, M, von Kalle, C, Rothe, M, Hoon, D S B, Gerasch, L, Figueiredo, C, Koehl, U, Blasczyk, R, Gutzmer, R, Stripecke, R
Publicado 2015

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study

por Dummer, R., Guminksi, A., Gutzmer, R., Lear, J.T., Lewis, K.D., Chang, A.L.S., Combemale, P., Dirix, L., Kaatz, M., Kudchadkar, R., Loquai, C., Plummer, R., Schulze, H.‐J., Stratigos, A.J., Trefzer, U., Squittieri, N., Migden, M.R.
Publicado 2019

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study

por Lear, J.T., Migden, M.R., Lewis, K.D., Chang, A.L.S., Guminski, A., Gutzmer, R., Dirix, L., Combemale, P., Stratigos, A., Plummer, R., Castro, H., Yi, T., Mone, M., Zhou, J., Trefzer, U., Kaatz, M., Loquai, C., Kudchadkar, R., Sellami, D., Dummer, R.
Publicado 2017

Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)

por Kähler, Katharina C., Hüning, S., Nashan, D., Meiss, F., Rafei-Shamsabadi, D. A., Rissmann, H., Colapietro, C., Livingstone, E., Maul, L. V., Heppt, M., Hassel, J. C., Gutzmer, R., Loquai, C., Heinzerling, L., Sachse, M. M., Bohne, A. S., Moysig, L., Peters, W., Rusch, J., Blome, C.
Publicado 2023

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

por Saiag, P., Gutzmer, R., Ascierto, P. A., Maio, M., Grob, J.-J., Murawa, P., Dreno, B., Ross, M., Weber, J., Hauschild, A., Rutkowski, P., Testori, A., Levchenko, E., Enk, A., Misery, L., Vanden Abeele, C., Vojtek, I., Peeters, O., Brichard, V. G., Therasse, P.
Publicado 2016

A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma

por O'Day, S, Pavlick, A, Loquai, C, Lawson, D, Gutzmer, R, Richards, J, Schadendorf, D, Thompson, J A, Gonzalez, R, Trefzer, U, Mohr, P, Ottensmeier, C, Chao, D, Zhong, B, de Boer, C J, Uhlar, C, Marshall, D, Gore, M E, Lang, Z, Hait, W, Ho, P
Publicado 2011

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

por Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Publicado 2016